A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma
- Determine the response rate to rebeccamycin analogue in children with relapsed or
- Determine the toxicity of this drug in these patients.
- Identify and establish in vitro biologic correlates of clinical responses and toxicity
of this drug in these patients.
OUTLINE: Patients receive rebeccamycin analogue IV over 1 hour once on days 1-5. Treatment
repeats every 3 weeks for at least 2 courses in the absence of disease progression or
PROJECTED ACCRUAL: This study will accrue up to 30 patients within 1.5 years.
Primary Purpose: Treatment
Response (complete response, very good partial response, or partial response)
Tanya Trippett, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|